Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE [bortezomib], and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma Who Are Not Eligible for a Bone Marrow Transplant

Trial Profile

A Randomized, Open-Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE [bortezomib], and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma Who Are Not Eligible for a Bone Marrow Transplant

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms LYM-3002 Study
  • Sponsors Janssen-Cilag; Takeda Oncology
  • Most Recent Events

    • 18 Oct 2018 Results assessing the overall survival and safety outcomes for patients in the long-term follow-up phase after the primary progression-free-survival endpoint was met, published in the Lancet Oncology.
    • 31 Aug 2018 Biomarkers information updated
    • 14 Jun 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top